Discovery of novel neuronal voltage-dependent calcium channel blockers based on emopamil left hand as a bioactive template

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 5, 2003, Pages 919-922

  Suzuki, Yuichi ^a   Yamamoto, Noboru ^a   Iimura, Yoichi ^a   Kawano, Koki ^a   Kimura, Teiji ^a   Nagato, Satoshi ^a   Ito, Koichi ^a   Komatsu, Makoto ^b   Norimine, Yoshihiko ^a   Kimura, Manami ^a   Teramoto, Tetsuyuki ^a   Kaneda, Yoshihisa ^a   Hamano, Takeshi ^a   Niidome, Tetsuhiro ^a   Yonaga, Masahiro ^a  

^a EISAI CO LTD   (Japan)

^b EBARA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL; EMOPAMIL;

ARTICLE; DRUG ACTIVITY; ELECTRIC POTENTIAL; HAND; SCREENING;

EID: 0037430663     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01070-3     Document Type: Article

References (23)

1. Kristian T., Siesjo B.K. Stroke. 29:1998;705.
2. (a) Graham S.H., Shiraisi K., Panter S.S., Simon R.P., Faden A.I. Neurosci. Lett. 110:1990;124 (b) Rothman S.M., Olney J.W. Ann. Neurol. 19:1986;105 (c) Dunlop K., Luebke J.I., Turner T.J. Trends Neurosci. 18:1995;89.
3. (a) Graham S.H., Shiraisi K., Panter S.S., Simon R.P., Faden A.I. Neurosci. Lett. 110:1990;124 (b) Rothman S.M., Olney J.W. Ann. Neurol. 19:1986;105 (c) Dunlop K., Luebke J.I., Turner T.J. Trends Neurosci. 18:1995;89.
4. (a) Graham S.H., Shiraisi K., Panter S.S., Simon R.P., Faden A.I. Neurosci. Lett. 110:1990;124 (b) Rothman S.M., Olney J.W. Ann. Neurol. 19:1986;105 (c) Dunlop K., Luebke J.I., Turner T.J. Trends Neurosci. 18:1995;89.
5. Kobayashi T., Mori Y. Eur. J. Pharmacol. 363:1998;1.
6. Nishizawa Y. Life Sci. 69:2001;369.
7. Randall A.D., Tsien R.W. J. Neurosci. 15:1995;2995.
8. (a) Mayer M.L., Miller R.J. Trends Pharmcol. Sci. 11:1990;254 (b) Osuga H., Hakim A.M. J. Cereb. Blood Flow Metab. 16:1996;629.
9. (a) Mayer M.L., Miller R.J. Trends Pharmcol. Sci. 11:1990;254 (b) Osuga H., Hakim A.M. J. Cereb. Blood Flow Metab. 16:1996;629.
10. Choi D.W. Trends Neurosci. 11:1988;465.
11. (a) Hu L., Todd R.R., Rafferty M.F., Feng M.R., Lotarski S.M., Rock D.M., Sinz M., Stoehr S.J., Taylor C.P., Weber M.L., Bowersox S.S., Miljanich G.P., Millerman E., Wang Y., Szoke B.G. J. Med. Chem. 42:1999;4239 (b) Hu L., Todd R.R., Rafferty M.F., Taylor C.P., Feng M.R., Kuo B., Lotarski S.M., Miljanich G.P., Millerman E., Siebers K.M., Szoke B.G. Bioorg. Med. Chem. 8:2000;1203 (c) Seko T., Kato M., Kohno H., Ono S., Hashimura K., Takimizu H., Nakai K., Maegawa H., Katsube N., Toda M. Bioorg. Med. Chem. Lett. 11:2001;2067 (d) Cox B., Denyer J.C. Expert Opin. Ther. Pat. 8:1998;1237.
12. (a) Hu L., Todd R.R., Rafferty M.F., Feng M.R., Lotarski S.M., Rock D.M., Sinz M., Stoehr S.J., Taylor C.P., Weber M.L., Bowersox S.S., Miljanich G.P., Millerman E., Wang Y., Szoke B.G. J. Med. Chem. 42:1999;4239 (b) Hu L., Todd R.R., Rafferty M.F., Taylor C.P., Feng M.R., Kuo B., Lotarski S.M., Miljanich G.P., Millerman E., Siebers K.M., Szoke B.G. Bioorg. Med. Chem. 8:2000;1203 (c) Seko T., Kato M., Kohno H., Ono S., Hashimura K., Takimizu H., Nakai K., Maegawa H., Katsube N., Toda M. Bioorg. Med. Chem. Lett. 11:2001;2067 (d) Cox B., Denyer J.C. Expert Opin. Ther. Pat. 8:1998;1237.
13. (a) Hu L., Todd R.R., Rafferty M.F., Feng M.R., Lotarski S.M., Rock D.M., Sinz M., Stoehr S.J., Taylor C.P., Weber M.L., Bowersox S.S., Miljanich G.P., Millerman E., Wang Y., Szoke B.G. J. Med. Chem. 42:1999;4239 (b) Hu L., Todd R.R., Rafferty M.F., Taylor C.P., Feng M.R., Kuo B., Lotarski S.M., Miljanich G.P., Millerman E., Siebers K.M., Szoke B.G. Bioorg. Med. Chem. 8:2000;1203 (c) Seko T., Kato M., Kohno H., Ono S., Hashimura K., Takimizu H., Nakai K., Maegawa H., Katsube N., Toda M. Bioorg. Med. Chem. Lett. 11:2001;2067 (d) Cox B., Denyer J.C. Expert Opin. Ther. Pat. 8:1998;1237.
14. (a) Hu L., Todd R.R., Rafferty M.F., Feng M.R., Lotarski S.M., Rock D.M., Sinz M., Stoehr S.J., Taylor C.P., Weber M.L., Bowersox S.S., Miljanich G.P., Millerman E., Wang Y., Szoke B.G. J. Med. Chem. 42:1999;4239 (b) Hu L., Todd R.R., Rafferty M.F., Taylor C.P., Feng M.R., Kuo B., Lotarski S.M., Miljanich G.P., Millerman E., Siebers K.M., Szoke B.G. Bioorg. Med. Chem. 8:2000;1203 (c) Seko T., Kato M., Kohno H., Ono S., Hashimura K., Takimizu H., Nakai K., Maegawa H., Katsube N., Toda M. Bioorg. Med. Chem. Lett. 11:2001;2067 (d) Cox B., Denyer J.C. Expert Opin. Ther. Pat. 8:1998;1237.
15. Yamamoto, N.; Suzuki, Y.; Iimura, Y.; Komatsu, M.; Kawano, K.; Kimura, T.; Norimine, Y.; Ito, K.; Nagato, S.; Niidome, T.; Teramoto, T.; Kimura, M.; Kaneda, Y.; Amino, H.; Ueno, M.; Hamano, T.; Nishizawa, Y.; Yonaga, M. Discovery of a potent neuron-selective calcium channel blocker: Structure-activity relationships and neuroprotective effects of novel piperazine derivatives; 222th ACS Natl Meeting, Aug 26-30 2001, Chicago; MEDI 051.
16. Abdel-Magid A.F., Carson K.G., Harris B.D., Maryanoff C.A., Shah R.D. J. Org. Chem. 61:1996;3849.
17. Yazawa H., Goto S. Tetrahedron Lett. 26:1985;3703.
18. 12b (b) David B., Samantha A., David L. Neuropharmacology. 32:1993;1195.
19. 13d (body weigh: 8-12 g) were used. Seizure was tested at 5 min after test compounds iv administration. Seizures were evoked by means of auditory stimulation (100 dB, 11 kHz) in mice placed singly under a perspex dome. Sounds were continued for 60 s. Test compounds at 10 mg/kg completely prevented sound-induced tonic convulsion in DBA/2 mice. (d) De Sarro G.B., Meldrum B.S., Nistico G. Br. J. Pharmacol. 93:1988;247.
20. 13d (body weigh: 8-12 g) were used. Seizure was tested at 5 min after test compounds iv administration. Seizures were evoked by means of auditory stimulation (100 dB, 11 kHz) in mice placed singly under a perspex dome. Sounds were continued for 60 s. Test compounds at 10 mg/kg completely prevented sound-induced tonic convulsion in DBA/2 mice. (d) De Sarro G.B., Meldrum B.S., Nistico G. Br. J. Pharmacol. 93:1988;247.
21. 13d (body weigh: 8-12 g) were used. Seizure was tested at 5 min after test compounds iv administration. Seizures were evoked by means of auditory stimulation (100 dB, 11 kHz) in mice placed singly under a perspex dome. Sounds were continued for 60 s. Test compounds at 10 mg/kg completely prevented sound-induced tonic convulsion in DBA/2 mice. (d) De Sarro G.B., Meldrum B.S., Nistico G. Br. J. Pharmacol. 93:1988;247.
22. 13d (body weigh: 8-12 g) were used. Seizure was tested at 5 min after test compounds iv administration. Seizures were evoked by means of auditory stimulation (100 dB, 11 kHz) in mice placed singly under a perspex dome. Sounds were continued for 60 s. Test compounds at 10 mg/kg completely prevented sound-induced tonic convulsion in DBA/2 mice. (d) De Sarro G.B., Meldrum B.S., Nistico G. Br. J. Pharmacol. 93:1988;247.
23. Furukawa T., Nukada T., Suzuki K., Fujita Y., Mori Y., Nishimura M., Yamanaka M. Br. J. Pharmacol. 121:1997;1136.